TY - JOUR
T1 - An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer
AU - McAndrews, Kathleen M.
AU - Paradiso, Francesca
AU - Stalnecker, Clint A.
AU - Chellakkan, Benson S.
AU - Thege, Fredrik I.
AU - Peng, David H.
AU - Moreno Diaz, Barbara A.
AU - Sugimoto, Hikaru
AU - Patel, Sarah I.
AU - Mahadevan, Krishnan K.
AU - Kirtley, Michelle L.
AU - Wills, Danielle
AU - Sockwell, Amari M.
AU - Fonseca, Andre Luis F.
AU - Liu, Yunhe
AU - Rajapakshe, Kimal I.
AU - Yee, Nathaniel G.
AU - Tran, Phuong Thao
AU - Omar, Huda Alchikh
AU - Tedeschi, Antonio
AU - Schischlik-Siegl, Fiorella
AU - Boghossian, Andrew S.
AU - Rees, Matthew G.
AU - Ronan, Melissa M.
AU - Roth, Jennifer A.
AU - Rudolph, Dorothea
AU - Aichinger, Martin
AU - Ebner, Florian
AU - Artemov, Artem V.
AU - Lipp, Jesse
AU - Pisarsky, Laura
AU - Herrmann, Valerie Laura
AU - Park, John
AU - Rippmann, Jörg F.
AU - Schaaf, Otmar
AU - Chandler, Vanessa
AU - Williams, Mariah
AU - Deckard, Charles E.
AU - Wang, Linghua
AU - Der, Channing J.
AU - Vellano, Christopher
AU - Guerrero, Paola A.
AU - Heffernan, Timothy P.
AU - Kalluri, Raghu
AU - Maitra, Anirban
N1 - Publisher Copyright:
Copyright © 2025 The Authors, some rights reserved.
PY - 2025/9/3
Y1 - 2025/9/3
N2 - KRAS is among the most frequently mutated oncogenes in cancer, and for decades, efforts at pharmacological blockade of its function in solid cancers have been unsuccessful. A notable advance in this endeavor is the recent development of small-molecule KRAS inhibitors, which enable direct targeting of the mutant oncoprotein. Here, we comprehensively evaluated the preclinical efficacy of BI-2493, a first-in-class allele-agnostic mutant-KRAS inhibitor (panKRASi), in pancreatic ductal adenocarcinoma (PDAC). We report effective tumor growth suppression across a broad range of models, including cell lines, patient-derived xenografts (PDXs), and syngeneic orthotopic models, and prolonged survival in genetically engineered mouse models. Overall, transcriptomic, proteomic, and phosphoproteomic profiling of panKRASi-treated models confirmed RAS pathway inhibition along with up-regulation of LKB1/AMPK (liver kinase B1/AMP-activated protein kinase) targets. In panKRASi-treated immune-replete models, we observed increased intratumoral CD8+ effector T cells and decreased infiltration of myeloid cells, along with remodeling of the tumor microenvironment (TME), enabling responses to immune checkpoint blockade. In the long term, emergence of resistance to panKRASi monotherapy was associated with increased YAP signaling within tumor cells and enhanced expression of immune checkpoints in the TME that impede effective T cell function. Our multifaceted approach identified potential combinatorial approaches for generating sustained responses to panKRASi.
AB - KRAS is among the most frequently mutated oncogenes in cancer, and for decades, efforts at pharmacological blockade of its function in solid cancers have been unsuccessful. A notable advance in this endeavor is the recent development of small-molecule KRAS inhibitors, which enable direct targeting of the mutant oncoprotein. Here, we comprehensively evaluated the preclinical efficacy of BI-2493, a first-in-class allele-agnostic mutant-KRAS inhibitor (panKRASi), in pancreatic ductal adenocarcinoma (PDAC). We report effective tumor growth suppression across a broad range of models, including cell lines, patient-derived xenografts (PDXs), and syngeneic orthotopic models, and prolonged survival in genetically engineered mouse models. Overall, transcriptomic, proteomic, and phosphoproteomic profiling of panKRASi-treated models confirmed RAS pathway inhibition along with up-regulation of LKB1/AMPK (liver kinase B1/AMP-activated protein kinase) targets. In panKRASi-treated immune-replete models, we observed increased intratumoral CD8+ effector T cells and decreased infiltration of myeloid cells, along with remodeling of the tumor microenvironment (TME), enabling responses to immune checkpoint blockade. In the long term, emergence of resistance to panKRASi monotherapy was associated with increased YAP signaling within tumor cells and enhanced expression of immune checkpoints in the TME that impede effective T cell function. Our multifaceted approach identified potential combinatorial approaches for generating sustained responses to panKRASi.
UR - https://www.scopus.com/pages/publications/105015529232
UR - https://www.scopus.com/pages/publications/105015529232#tab=citedBy
U2 - 10.1126/scitranslmed.adt5511
DO - 10.1126/scitranslmed.adt5511
M3 - Article
C2 - 40901924
AN - SCOPUS:105015529232
SN - 1946-6234
VL - 17
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 814
M1 - eadt5511
ER -